JP2013521314A - 癌の処置のためのチゲサイクリンの使用 - Google Patents
癌の処置のためのチゲサイクリンの使用 Download PDFInfo
- Publication number
- JP2013521314A JP2013521314A JP2012556354A JP2012556354A JP2013521314A JP 2013521314 A JP2013521314 A JP 2013521314A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2012556354 A JP2012556354 A JP 2012556354A JP 2013521314 A JP2013521314 A JP 2013521314A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- mitochondrial
- tigecycline
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31241010P | 2010-03-10 | 2010-03-10 | |
| US61/312,410 | 2010-03-10 | ||
| PCT/CA2011/000258 WO2011109899A1 (en) | 2010-03-10 | 2011-03-10 | Use of tigecycline for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013521314A true JP2013521314A (ja) | 2013-06-10 |
| JP2013521314A5 JP2013521314A5 (https=) | 2014-04-24 |
Family
ID=44562767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556354A Withdrawn JP2013521314A (ja) | 2010-03-10 | 2011-03-10 | 癌の処置のためのチゲサイクリンの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120329761A1 (https=) |
| EP (1) | EP2544692A4 (https=) |
| JP (1) | JP2013521314A (https=) |
| CN (1) | CN102821769A (https=) |
| CA (1) | CA2790240A1 (https=) |
| WO (1) | WO2011109899A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013010256A1 (en) * | 2011-07-15 | 2013-01-24 | University Health Network | Combination treatment for cancer |
| WO2014029016A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer |
| CA2883238C (en) | 2012-08-31 | 2021-11-23 | Tetraphase Pharmaceuticals, Inc. | Tetracycline compounds |
| CN105143463A (zh) | 2013-02-25 | 2015-12-09 | 诺华股份有限公司 | 新的雄激素受体突变 |
| CN103142624A (zh) * | 2013-03-01 | 2013-06-12 | 西南大学 | 抗生素替加环素在制备抗癌药物中的应用 |
| US9937161B2 (en) | 2013-03-06 | 2018-04-10 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| IL264878B (en) * | 2016-08-30 | 2022-06-01 | Tetraphase Pharmaceuticals Inc | Tetracycline compounds and methods of treatment |
| HUE066360T2 (hu) | 2016-10-19 | 2024-07-28 | Tetraphase Pharmaceuticals Inc | Eravaciklin kristályformái |
| KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
| CN109331026A (zh) * | 2018-04-21 | 2019-02-15 | 温州医科大学附属第医院 | 替加环素在制备抗多发性骨髓瘤药物中的应用 |
| CA3102264A1 (en) * | 2018-06-19 | 2019-12-26 | Lunella Biotech, Inc. | "energetic" cancer stem cells (e-cscs): a new hyper-metabolic and proliferative tumor cell phenotype, driven by mitochondrial energy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837696A (en) * | 1997-01-15 | 1998-11-17 | The Research Foundation Of State University Of New York | Method of inhibiting cancer growth |
| AU1763201A (en) * | 1999-11-10 | 2001-06-06 | Mitokor | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
| AU2002214487A1 (en) * | 2000-11-10 | 2002-05-21 | Mitotech Ab | Method for inducing apoptiosis |
| RU2300380C2 (ru) * | 2001-10-05 | 2007-06-10 | Тетрадженекс Фармасьютикалс, Инк. | Производные тетрациклина и способы их применения |
| WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
| US20050148553A1 (en) * | 2003-09-05 | 2005-07-07 | Testa Raymond T. | Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis |
| AR057032A1 (es) * | 2005-05-27 | 2007-11-14 | Wyeth Corp | Tigeciclina y metodos de preparacion |
-
2011
- 2011-03-10 WO PCT/CA2011/000258 patent/WO2011109899A1/en not_active Ceased
- 2011-03-10 CN CN201180013184XA patent/CN102821769A/zh active Pending
- 2011-03-10 EP EP11752777.0A patent/EP2544692A4/en not_active Withdrawn
- 2011-03-10 US US13/582,842 patent/US20120329761A1/en not_active Abandoned
- 2011-03-10 CA CA2790240A patent/CA2790240A1/en not_active Abandoned
- 2011-03-10 JP JP2012556354A patent/JP2013521314A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN102821769A (zh) | 2012-12-12 |
| CA2790240A1 (en) | 2011-09-15 |
| WO2011109899A1 (en) | 2011-09-15 |
| EP2544692A4 (en) | 2013-08-07 |
| US20120329761A1 (en) | 2012-12-27 |
| EP2544692A1 (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013521314A (ja) | 癌の処置のためのチゲサイクリンの使用 | |
| AU2013342267B2 (en) | Small molecule inhibitors of MALT1 | |
| JP5688288B2 (ja) | がんの処置のための相乗的な医薬の組合せ | |
| JP6132833B2 (ja) | 抗癌療法としての正常細胞および腫瘍細胞の小分子trail遺伝子誘導 | |
| US9771625B2 (en) | Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer | |
| US20210186993A1 (en) | Combination therapies targeting mitochondria for cancer therapy | |
| TWI759316B (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| EP2880014A1 (en) | Compounds for the treatment of mtor pathway related diseases | |
| CN102791260A (zh) | 低氧诱导因子抑制剂的用途 | |
| WO2015061832A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| JP2009543874A (ja) | チアゾリジノン誘導体 | |
| US20140221301A1 (en) | Combination treatment for cancer | |
| WO2014029016A1 (en) | Compositions comprising a glycylcycline and a tyrosine kinase inhibitor for treating cancer | |
| US11583509B2 (en) | Compound for treating cancer and diabetes | |
| US20220016118A1 (en) | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof | |
| EP3405194B1 (en) | A temporary inhibitor of p53 in combination with an anticancer agent for use in the preventing or reducing cancer relapse | |
| US20230201168A1 (en) | New therapy for the treatment of tumors | |
| JP2024506847A (ja) | がんを処置および改善するための方法 | |
| WO2019168177A1 (ja) | 癌の予防または治療剤 | |
| Liu et al. | Xiao Liu1, 2†, Zhengcong Cao1†, Nannan Liu3†, Guangxun Gao2, Mingrui Du4, Yingwen Wang1, Boyang Cheng1, Maorong Zhu1, Bo Jia2, Luxiang Pan1, Wangqian Zhang1, Yuran Jiang5, Wei He1, Linlin Xu2, Wei Zhang1, Qunxing An2*, Qingdong Guo2* and Jintao Gu1 | |
| AU2023313328A1 (en) | Cancer combination therapy including a bcl-2 inhibitor | |
| Ocio et al. | Deacetylase Inhibition in Haematological Malignancies–Advanced T-cell Lymphoma, Hodgkin’s Lymphoma, Multiple Myeloma, Acute Myelogenous Leukaemia and Myelodysplastic Syndrome | |
| Kokkinis et al. | Liposomal Encapsulated Curcumin Attenuates Lung Cancer Proliferation, Migration and Apoptosis | |
| NZ622752A (en) | Romidepsin and 5 - azacitidine for use in treating lymphoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140310 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20141008 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141008 |